60 Degrees Pharmaceuticals, Inc. SXTP 深 滬
已收盤 01-02 16:00:00 美东时间
0.5159
+0.008
+1.50%
華盛通- 最 高0.536
- 今 開0.5183
- 成交量 15.63万股
- 最 低 0.5015
- 昨 收 0.5083
- 總市值 161.09万
- 52周最高 8.00
- 市盈率 靜 --
- 換手率 5.00%
- 52周最低 0.45
- 委 比 88.60%
- 總股本 312.26万
- 歷史最高 519.00
- 量 比 0.33
- 振 幅 6.79%
- 歷史最低 0.5015
- 每 手 1
- 風險率 1.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多60 Degrees Pharmaceuticals Identifies Babesia Parasite In 24% Of Participants In Group Of 50 Patients With Chronic Fatigue
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection
2025-12-29 21:11
60 Degrees Pharma To Expand ARAKODA Sales And Marketing, Adding Reps, GoodRx Partnership And Enhanced Digital Campaign
6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaignAdditional clinical
2025-12-11 21:19
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
2025-12-01 14:33
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $2.8
Ascendiant Capital analyst Lucas Ward maintains 60 Degrees (NASDAQ:SXTP) with a Buy and lowers the price target from $3 to $2.8.
2025-11-28 18:57
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
HC Wainwright & Co. Assumes 60 Degrees at Buy, Announces Price Target of $6
HC Wainwright & Co. analyst Matthew Keller assumes 60 Degrees (NASDAQ:SXTP) with a Buy rating and announces Price Target of $6.
2025-11-14 20:48
60 Degrees Q3 EPS $(0.66) Beats $(1.21) Estimate, Sales $437.602K Beat $400.000K Estimate
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(1.21) by 45.45 percent. This is a 85.81 percent increase over losses of $(4.65) per share from the
2025-11-14 02:54
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
60 Degrees Pharmaceuticals, Inc. has submitted a Breakthrough Therapy Designation request to the FDA for tafenoquine, a malaria drug, targeting babesiosis treatment. The company is conducting clinical trials to confirm its efficacy in immunosuppressed patients with relapsing babesiosis. The first patient in their expanded access study tested negative for the infection using highly sensitive tests. Remaining patients will complete the study by Oct...
2025-10-15 11:14
60 Degrees Pharma Launches B-FREE Study, First-Ever Trial for Chronic Babesiosis Treatment
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the name
2025-10-09 19:18
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
60 Degrees Pharmaceuticals宣布启动名为B-FREE的慢性巴贝斯虫病II期临床试验，该研究旨在评估药物ARAKODA（tafenoquine）的效果。公司通过社交媒体邀请患者参与命名竞赛，最终选定B-FREE，并捐赠5000美元支持相关疾病研究机构。研究计划招募100名患者，评估药物疗效及安全性，预计11月初启动，持续约12个月。
2025-10-09 11:04
